Impact of weight loss on obesity-related complications and direct healthcare costs in Japan: A modelling study

IF 5.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes, Obesity & Metabolism Pub Date : 2025-03-20 DOI:10.1111/dom.16306
Ataru Igarashi PhD, Silvia Capucci MSc, Riku Ota MPH, Shogo Wada PhD, Volker Schnecke PhD
{"title":"Impact of weight loss on obesity-related complications and direct healthcare costs in Japan: A modelling study","authors":"Ataru Igarashi PhD,&nbsp;Silvia Capucci MSc,&nbsp;Riku Ota MPH,&nbsp;Shogo Wada PhD,&nbsp;Volker Schnecke PhD","doi":"10.1111/dom.16306","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>Body mass index (BMI) in Japan has increased over the past decades, leading to corresponding increases in the risks of complications such as type 2 diabetes (T2D). We modelled the impact of weight loss on the incidence of 10 specific complications and resulting healthcare costs in a Japanese cohort.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>We adapted our value of weight loss simulation model to represent a cohort of 100,000 Japanese individuals aged 20–69 years with a BMI of 25–50 kg/m<sup>2</sup>. Complication prevalence data were from the Medical Data Vision electronic health record database, and costs were identified using a targeted literature review and the IQVIA claims database. The impact of weight loss was modelled from 2024 to 2029.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Total estimated direct medical costs associated with complications were 171.7 million US dollars (USD) or 25.6 billion Japanese yen (JPY) in 2024, projected to increase to 234.9 million USD (35.1 billion JPY) by 2029. A 10% or 15% lower weight across the population was estimated to be associated with a lower incidence of all complications, particularly sleep apnoea, T2D and hypertension. The resulting estimated cumulative cost reductions amounted to 34.6 million USD (5.2 billion JPY) for a 10% weight loss and 47.7 million USD (7.1 billion JPY) for a 15% weight loss over 5 years, largely arising from reductions in T2D.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Weight loss in the Japanese population has the potential to drive major reductions in healthcare costs via prevention of complications associated with higher BMI and consequent reductions in costs associated with these complications. Greater weight loss is likely to be associated with greater cost reductions. Our analysis highlights the importance of prompt weight management support for people living with obesity.</p>\n </section>\n </div>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"27 6","pages":"3017-3024"},"PeriodicalIF":5.7000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.16306","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16306","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aim

Body mass index (BMI) in Japan has increased over the past decades, leading to corresponding increases in the risks of complications such as type 2 diabetes (T2D). We modelled the impact of weight loss on the incidence of 10 specific complications and resulting healthcare costs in a Japanese cohort.

Materials and Methods

We adapted our value of weight loss simulation model to represent a cohort of 100,000 Japanese individuals aged 20–69 years with a BMI of 25–50 kg/m2. Complication prevalence data were from the Medical Data Vision electronic health record database, and costs were identified using a targeted literature review and the IQVIA claims database. The impact of weight loss was modelled from 2024 to 2029.

Results

Total estimated direct medical costs associated with complications were 171.7 million US dollars (USD) or 25.6 billion Japanese yen (JPY) in 2024, projected to increase to 234.9 million USD (35.1 billion JPY) by 2029. A 10% or 15% lower weight across the population was estimated to be associated with a lower incidence of all complications, particularly sleep apnoea, T2D and hypertension. The resulting estimated cumulative cost reductions amounted to 34.6 million USD (5.2 billion JPY) for a 10% weight loss and 47.7 million USD (7.1 billion JPY) for a 15% weight loss over 5 years, largely arising from reductions in T2D.

Conclusions

Weight loss in the Japanese population has the potential to drive major reductions in healthcare costs via prevention of complications associated with higher BMI and consequent reductions in costs associated with these complications. Greater weight loss is likely to be associated with greater cost reductions. Our analysis highlights the importance of prompt weight management support for people living with obesity.

Abstract Image

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
日本减肥对肥胖相关并发症和直接医疗费用的影响:一项模型研究
目的:在过去的几十年里,日本的身体质量指数(BMI)不断上升,导致2型糖尿病(T2D)等并发症的风险相应增加。我们在一个日本队列中建立了减肥对10种特定并发症发生率和由此产生的医疗费用的影响模型。材料和方法:我们调整了体重减轻模拟模型的值,以代表10万名年龄在20-69岁、体重指数为25-50 kg/m2的日本人。并发症患病率数据来自医疗数据视觉电子健康记录数据库,成本通过有针对性的文献综述和IQVIA索赔数据库确定。研究人员从2024年到2029年模拟了减肥的影响。结果:与并发症相关的总直接医疗费用估计在2024年为1.717亿美元(256亿日元),预计到2029年将增加到2.349亿美元(351亿日元)。据估计,人群中体重降低10%或15%与所有并发症的发生率降低有关,特别是睡眠呼吸暂停、T2D和高血压。在5年的时间里,如果减重10%,累计成本将减少3460万美元(52亿日元),如果减重15%,累计成本将减少4770万美元(71亿日元),这主要得益于T2D的减少。结论:日本人口的体重减轻有可能通过预防与高BMI相关的并发症以及随之而来的与这些并发症相关的成本降低,从而推动医疗保健成本的大幅降低。更大的体重减轻可能与更大的成本降低有关。我们的分析强调了及时为肥胖患者提供体重管理支持的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism 医学-内分泌学与代谢
CiteScore
10.90
自引率
6.90%
发文量
319
审稿时长
3-8 weeks
期刊介绍: Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
期刊最新文献
Trends and disparities in type 1 diabetes-related mortality in the United States, 1999-2023. High-intensity interval training induces lactate dehydrogenase B lactylation to inhibit hepatic lipogenesis to alleviate metabolic dysfunction-associated fatty liver disease. Real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi-site retrospective study. Obesity-related distress and obesity burnout: Towards a conceptual framework for disease-specific emotional burden in obesity. Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double-blind, placebo-controlled trial (LIGHT 2).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1